# Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

> **NCT06780670** · PHASE2,PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 443 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Investigators choice of SoC
- **DRUG:** AAA817
- **DRUG:** AAA817
- **DRUG:** AAA817

## Key facts

- **NCT ID:** NCT06780670
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-27
- **Primary completion:** 2028-06-27
- **Final completion:** 2033-07-19
- **Target enrollment:** 443 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06780670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06780670, "Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06780670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*